Vaccine – Salmon Science

Vaccine

Development of an RLO vaccine: Proof-of-Concept to commercial application

By Romano Studer|2023-04-21T16:09:45+10:00April 20th, 2023|0 Comments

Pilchard orthomyxovirus fast-track proof-of-concept vaccine

By Romano Studer|2023-04-21T16:12:41+10:00April 20th, 2023|0 Comments

Development of Pilchard orthomyxo virus vaccine for salmonids

By Romano Studer|2023-04-21T16:09:47+10:00April 20th, 2023|0 Comments

Development of a vaccine for cutaneous erosion disease of farmed Atlantic salmon

By Romano Studer|2023-04-21T16:09:43+10:00April 20th, 2023|0 Comments

Tasmanian Aquabirnavirus vaccine development: Towards achieving pan-specific protection of cultured salmonids in Australia using multivalent vaccines

By Romano Studer|2023-04-21T16:14:20+10:00April 20th, 2023|0 Comments

Aquareovirus (TSRV) vaccine development for the Tasmanian salmonid aquaculture industry

By Romano Studer|2023-04-21T16:03:59+10:00April 20th, 2023|0 Comments

Atlantic Salmon Aquaculture Subprogram: Rickettsia-like organism vaccine development for the salmonid aquaculture industry

By Romano Studer|2023-04-21T16:19:41+10:00April 20th, 2023|0 Comments

TSGA IPA: The Australian Aquatic Animal Health and Vaccine Centre: First Phase to Establish Atlantic Salmon Biosecure Fish Facility Capabilities and Develop Strategy for an Australian Centre of Excellence

By Romano Studer|2023-04-21T16:15:01+10:00April 20th, 2023|0 Comments

Aquafin CRC – Atlantic Salmon Aquaculture Subprogram – development of a vaccine for amoebic gill disease: genomic and cDNA library screening for antigen discovery

By Romano Studer|2023-04-21T16:00:16+10:00April 20th, 2023|0 Comments

Aquafin CRC – Atlantic Salmon Aquaculture Subprogram: development of an AGD vaccine: phase II

By Romano Studer|2023-04-21T16:03:43+10:00April 20th, 2023|0 Comments

Aquafin CRC – Atlantic Salmon Aquaculture Subprogram: molecular assessment of resistance to AGD in Atlantic salmon

By Romano Studer|2023-04-21T16:03:54+10:00April 20th, 2023|0 Comments

Seafood CRC: Amoebic Gill Disease vaccine phase III; Sea-based trials, vaccine refinement and commercialisation

By Romano Studer|2023-04-21T16:13:27+10:00April 20th, 2023|0 Comments